Core Viewpoint - Koyuan Pharmaceutical has decided to terminate the issuance of shares for asset acquisition and related fundraising due to changes in the market environment, aiming to protect the long-term interests of all shareholders [1] Group 1: Termination of Acquisition - The board of Koyuan Pharmaceutical has approved the termination of the share issuance for acquiring 99.42% of Hongjitang for a consideration of 3.58 billion yuan and raising up to 700 million yuan in supporting funds [1] - The termination is described as a prudent decision to maintain the long-term interests of shareholders, with no significant adverse impact on the company's current operations [1] Group 2: Business Performance - For the first three quarters of the year, Koyuan Pharmaceutical reported revenue of 303 million yuan, a year-on-year decrease of 8.5%, and a net profit attributable to shareholders of 31.47 million yuan, down 20.7% [2] - The company's operating cash flow net amount was 27.24 million yuan, showing a year-on-year increase of 14.1% [2] Group 3: Strategic Developments - Koyuan Pharmaceutical's subsidiary, Linuo Pharmaceutical, has had its intelligent manufacturing project for injectables included in the list of major industrial projects for the province's new and old kinetic energy conversion in 2025 [2] - The intelligent manufacturing project, completed on September 28, covers an area of approximately 46,000 square meters and includes key areas such as quality inspection and R&D buildings, high-end injectable production workshops, and a comprehensive intelligent warehouse [2] - The project aims to leverage industrial internet, artificial intelligence, and big data technologies to create a comprehensive smart control system from R&D to production, meeting the standards of China GMP, US FDA, and EU GMP [2][3] Group 4: Future Outlook - Koyuan Pharmaceutical plans to use the inclusion of its project as an opportunity to increase innovation investment and empower industrial upgrades, contributing to the high-quality development of the pharmaceutical industry in Shandong Province [3]

Core Viewpoint - Koyuan Pharmaceutical announced the termination of its plan to issue shares for asset acquisition and related fundraising, withdrawing its application documents [1][2]. Group 1: Transaction Details - The company intended to acquire 99.42% of Shandong Hongjitang Pharmaceutical Group Co., Ltd. from 38 trading parties, including Linuo Investment Holding Group Co., Ltd. and Linuo Group Co., Ltd. [1][2]. - The transaction was valued at approximately 3.581 billion yuan, excluding the fundraising amount [2]. Group 2: Business Implications - The acquisition was expected to extend Koyuan Pharmaceutical's main business into traditional Chinese medicine and health products, enhancing operational efficiency and reducing costs [2]. - The company aimed to create a large-scale, well-known health platform in the pharmaceutical industry, improving its overall strength and value [2]. Group 3: Reason for Termination - The termination was due to changes in the overall market environment since the initial announcement of the transaction, leading to a decision made in the interest of all shareholders [2].

Key Points - Guizhou Moutai elected Chen Hua as the chairman of the fourth board of directors and plans to repurchase shares between RMB 1.5 billion and RMB 3 billion [1] - Tianfeng Securities is under investigation by the China Securities Regulatory Commission for suspected violations of information disclosure and illegal financing [1] Share Buybacks - Demai Technology raised the upper limit for share repurchase to RMB 45 per share [5] - Jianbang Technology plans to repurchase shares worth between RMB 15 million and RMB 30 million [5] - Huayuan Holdings intends to repurchase shares worth between RMB 30 million and RMB 60 million [5] Major Investments - Jinling Pharmaceutical plans to invest RMB 893 million in hospital expansion projects [7] - Dongfang Mingzhu intends to invest approximately RMB 500 million to establish a partnership and acquire part of the equity of New H3C [7] - Chang'an Automobile aims to establish a robotics company to develop innovative products and solutions [7] Mergers and Acquisitions - Kaizhong Co. plans to acquire 60% of Anhui Tuosheng's equity, with stock resuming trading on December 1 [7] - Youa Co. has resumed the review process for issuing shares and cash to purchase assets [7] - Jiasheng Technology intends to acquire controlling interest in Shudun Information Technology Co., with stock continuing to be suspended [7] Financing Activities - Shenzhen Energy plans to apply for a public bond issuance with a total scale not exceeding RMB 20 billion [7] - Huakong Saige has terminated its specific object stock issuance [7]

格隆汇11月28日丨科源制药(301281.SZ)公布，公司原拟向力诺投资控股集团有限公司、力诺集团股份 有限公司等38名交易对方发行股份购买其持有的山东宏济堂制药集团股份有限公司99.42%股份。同 时，公司拟向不超过35名符合条件的特定对象发行股份募集配套资金。 自公司筹划并首次公告本次交易以来，公司严格按照相关法律法规及规范性文件要求，积极组织交易各 相关方推进本次重组工作。但鉴于市场整体环境情况较本次重组筹划之初发生了一定变化，为维护公司 全体股东长期利益，经公司与交易各相关方友好协商、认真研究和充分论证，基于审慎性考虑，决定终 止本次重组事项。 ...

证券日报网讯 11月28日晚间，科源制药发布公告称，近日，公司收到中信建投证券发来的通知，鉴于 原独立财务顾问主办人孙林先生工作变动，不再担任本次交易的独立财务顾问主办人。本次独立财务顾 问主办人减少后，中信建投证券原委派的独立财务顾问主办人杨慧泽先生、王辉先生将继续担任本次交 易的独立财务顾问主办人，履行本次交易的相关职责。 （文章来源：证券日报） ...

Core Viewpoint - The company has decided to terminate its plan to issue shares for the acquisition of a 99.42% stake in Shandong Hongjitang Pharmaceutical Group Co., Ltd. and to withdraw related application documents [1] Group 1 - The company initially intended to issue shares to 38 counterparties, including Linuo Investment Holding Group Co., Ltd. and Linuo Group Co., Ltd. [1] - The company planned to raise supporting funds by issuing shares to no more than 35 qualified specific objects [1] - The board of directors has approved the resolution to terminate the share issuance for asset acquisition and related transactions [1]

Core Viewpoint - The company has decided to terminate its plan to issue shares for the acquisition of a 99.42% stake in Shandong Hongjitang Pharmaceutical Group Co., Ltd. and to withdraw related application documents [1] Group 1 - The company originally intended to issue shares to 38 counterparties, including Linuo Investment Holding Group Co., Ltd. and Linuo Group Co., Ltd. [1] - The company planned to raise supporting funds by issuing shares to no more than 35 qualified specific objects [1] - The board of directors approved the resolution to terminate the share issuance for asset acquisition and related transactions [1]

Core Viewpoint - Koyuan Pharmaceutical announced the termination of its planned acquisition of 99.42% of Shandong Hongjitang Pharmaceutical Group Co., Ltd. due to changes in the overall market environment since the initial announcement of the transaction [1] Group 1: Transaction Details - The company initially intended to issue shares to 38 counterparties, including Linuo Investment Holding Group Co., Ltd. and Linuo Group Co., Ltd., to acquire the majority stake in Shandong Hongjitang [1] - Additionally, the company planned to issue shares to no more than 35 qualified specific investors to raise supporting funds [1] Group 2: Reasons for Termination - Koyuan Pharmaceutical stated that it has been actively organizing the transaction in accordance with relevant laws and regulations since the planning and initial announcement of the transaction [1] - The decision to terminate the restructuring was made after friendly consultations and thorough research with all relevant parties, based on a prudent consideration of the changes in the market environment [1]

每经头条（nbdtoutiao）——已有75人遇难，1名死者为消防员，还有10名消防员受伤！记者现场直击香 港大埔火灾：燃烧的宏福苑，五级大火的五个谜团 （记者 曾健辉） 每经AI快讯，科源制药（SZ 301281，收盘价：29.28元）11月28日晚间发布公告称，公司第四届第十五 次董事会会议于2025年11月28日在公司会议室召开。会议审议了《关于终止发行股份购买资产并募集配 套资金暨关联交易事项并撤回申请文件的议案》等文件。 2025年1至6月份，科源制药的营业收入构成为：医药制造业占比100.0%。 截至发稿，科源制药市值为32亿元。 ...

一、董事会会议召开情况 山东科源制药股份有限公司 关于召开终止发行股份购买资产并募集配套资金暨关联交易 证券代码：301281 证券简称：科源制药 公告编号：2025-081 事项投资者说明会的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 公司董事长兼总经理、副总经理兼董事会秘书；交易对方代表、标的公司代 表、独立财务顾问主办人等相关人员将出席本次投资者说明会（如有特殊情况， 参与人员可能会有调整，具体以当天实际参会人员为准）。 四、投资者参加方式 投资者可以在上述会议召开时间段内登录价值在线（www.ir-online.cn）参 与本次说明会，与公司出席人员进行互动交流。公司将在信息披露规定允许范围 内就投资者普遍关注的问题进行回答。 山东科源制药股份有限公司（以下简称"公司"）于 2025 年 11 月 28 日召 开第四届董事会第十五次会议，审议通过了《关于终止发行股份购买资产并募集 配套资金暨关联交易事项并撤回申请文件的议案》，同意公司终止发行股份购买 资产并募集配套资金暨关联交易事项（以下简称"本次交易"）并撤回申请文件。 具体内容详见公司同 ...